Over the past 15 years, many new treatments for psoriasis have been developed that achieve better, more rapid, and durable efficacy. The availability of these psoriasis therapies is valuable to both patients and clinicians and offers more options for shared decision making. However, solely relying on the registrational clinical trials that demonstrate the efficacy of these drugs does not allow a full understanding of the relative effect of these medicines weighed against each other. The challenge for the clinician is to go beyond the absolute efficacy of medications to an understanding of their comparative merit and then incorporate this consideration into broader concerns that govern appropriate treatment decisions.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Strober B, Gordon KB. Comparative Effectiveness Studies for Psoriasis—The Methods Matter. JAMA Dermatol. 2020;156(3):253–255. doi:10.1001/jamadermatol.2019.4025
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: